The research team, led by scientists at the International Centre for Recurrent Head and Neck Cancer based at the Royal Marsden Hospital and the London School of Hygiene & Tropical Medicine, assembled an extraordinary data infrastructure to answer a deceptively simple question: how long do head and neck cancer patients actually wait from first referral to the start of treatment, and which factors push some patients into dangerously long delays? To do this, they linked the national Cancer Registry with the Cancer Waiting Times dataset, Hospital Episodes Statistics, and national Radiotherapy and Chemotherapy datasets, creating a real-world picture of the entire diagnostic and treatment pathway that no single dataset could provide on its own.

The headline numbers are stark. Of the 30,506 patients analysed, 43 percent experienced what the study defines as treatment delay, meaning more than 62 days elapsed between referral and the start of first treatment, whether that was surgery or chemoradiation. The picture becomes even more concerning when the researchers examined the most extreme waits. Among patients whose primary treatment was surgery, 11 percent waited more than 90 days. For those treated primarily with radiotherapy or chemoradiation, the figure rose to 20 percent, one in five patients waiting more than three months from referral to the beginning of a treatment course on which their survival may depend.

Why does timing matter so much in this particular cancer? Head and neck tumours, which arise in the mouth, throat, voice box, nose and salivary glands, are among the most time-sensitive malignancies in oncology. Unlike some slow-growing cancers where a few extra weeks make little biological difference, head and neck tumours can progress rapidly, and a substantial body of evidence links even short treatment delays to worse outcomes. A landmark systematic review and meta-analysis published in the BMJ in 2020 estimated that delays in cancer treatment translate directly into excess mortality, with the risk of death rising measurably for every additional week of waiting. Studies of head and neck cancer specifically, including analyses of the United States National Cancer Database and systematic reviews published in JAMA Otolaryngology, have consistently shown that increasing time to treatment initiation is associated with poorer survival, larger tumours at treatment, and in some cases pathological upstaging, where the tumour is found to have advanced further than initial assessments suggested.

Against this biological backdrop, the new study’s identification of the strongest predictor of delay carries real weight. Patients who entered the cancer pathway through a non-urgent referral route, rather than the urgent suspected cancer referral pathway designed to fast-track people with red-flag symptoms, faced dramatically higher odds of long delay. After adjusting for other factors in multivariable logistic regression models, non-urgent referral was associated with an adjusted odds ratio of 4.07 for long delay, with a confidence interval of 3.54 to 4.68. In practical terms, patients referred through routine channels were roughly four times more likely to experience a treatment delay exceeding 62 days than those referred urgently. Notably, non-urgent referrals accounted for 30 percent of all patients in the cohort, meaning nearly a third of people who ultimately turned out to have head and neck cancer were not flagged as urgent when they first entered the system.

This finding points to a fundamental diagnostic challenge. The early symptoms of head and neck cancer, including persistent sore throat, hoarseness, mouth ulcers that fail to heal, difficulty swallowing, and unexplained lumps in the neck, overlap heavily with far more common and benign conditions. Distinguishing a cancer that will kill from a viral infection that will resolve within days is one of the hardest triage tasks in primary care, and the study’s authors argue that improving this recognition is where interventions should focus. Public and primary care awareness of head and neck cancer symptoms, they suggest, is a critical lever for shifting more patients onto the urgent referral pathway where rapid investigation follows.

But referral route was not the only determinant of delay. The researchers found that patients whose initial assessment took place at non-specialist hospitals, referred to in the study as spoke hospitals rather than the specialist hub centres where head and neck cancer expertise is concentrated, faced higher odds of delay. This reflects a broader tension in modern NHS organisation: the centralisation of complex cancer surgery into fewer, higher-volume specialist centres improves outcomes and quality, but it can add steps, transfers and logistical friction to the patient journey, particularly for those who first present at a district general hospital and must then be referred onward for specialist assessment. The study also found that patients with cancers arising outside the oropharynx, the part of the throat that includes the tonsils and base of the tongue, experienced longer waits, likely reflecting the more indistinct symptom profiles of tumours in sites such as the voice box, nasal cavity and salivary glands. Higher socio-economic deprivation emerged as a further risk factor, adding to a long record of evidence that cancer waits in England are systematically worse for patients from poorer communities, who may present later, navigate the system with less support, and face additional barriers at every stage of the pathway.

One of the study’s most technically interesting contributions is its demonstration that the drivers of delay differ fundamentally between the two main treatment modalities. Patients destined for primary surgery and patients destined for primary chemoradiation follow different pathways, and the factors that slow each group down are not identical. Surgical patients typically require pre-operative assessment, anaesthetic review and theatre capacity, while radiotherapy patients depend on planning processes, mould fabrication, and linear accelerator capacity, and those receiving concurrent chemotherapy face additional pharmaceutical and supportive care requirements. The finding that long delays were twice as common in the chemoradiation group, 20 percent versus 11 percent, suggests that the non-surgical pathway carries a distinct and heavier burden of system-level bottlenecks. The authors argue that any strategy to reduce waiting times must acknowledge and address these modality-specific drivers rather than treating the cancer pathway as a single undifferentiated queue.

The study’s methodology deserves attention because it exemplifies a growing trend in oncology research: the use of real-world data at national scale to answer questions that clinical trials, with their selected populations and controlled conditions, cannot address. By linking five national datasets covering registration, waiting times, hospital admissions, radiotherapy and chemotherapy, the researchers captured the full continuum of care for essentially an entire national population of head and neck cancer patients over the study period. The analyses were conducted in RStudio, and the work was funded by the International Centre for Recurrent Head and Neck Cancer, with ethics approval from the London School of Hygiene and Tropical Medicine Ethics Committee. The data were provided under licence by NHS Digital’s National Disease Registration Service, and the underlying data cannot be shared publicly, reflecting the governance constraints that accompany such sensitive linked health records.

The implications reach well beyond the borders of England. Health systems worldwide are grappling with post-pandemic backlogs, rising cancer incidence and constrained diagnostic capacity, and head and neck cancer services have been repeatedly identified as among those with the longest treatment waits. The study’s conclusions offer a roadmap: optimise referral pathways so that more patients with suspicious symptoms enter the urgent route, invest in symptom awareness among both the public and general practitioners, design diagnostic pathways that minimise transfers between spoke and hub hospitals, and build separate solutions for the surgical and radiotherapy arms of the service. The authors also point to emerging research programmes, such as the NIHR-funded EVEREST-HN initiative, which is developing a patient-reported symptom-based risk stratification system to redesign the suspected head and neck cancer referral pathway, as the kind of innovation the findings demand. For the one in five patients whose radiotherapy begins more than three months after their first referral, and for the 43 percent overall who wait beyond the 62-day standard, the message of this study is unambiguous: the delay is measurable, its causes are identifiable, and its consequences for survival are too well documented to ignore.

Subject of Research: Waiting times and determinants of treatment delay for head and neck cancer patients in England

Article Title: Waiting times and determinants of delay for head and neck cancer in England—a population cohort study using real world data

Article References: Jashek-Ahmed, F., Almilaji, O., Cowling, T. E., Hamilton, D. W., Walker, K., & Paleri, V. (2026). Waiting times and determinants of delay for head and neck cancer in England—a population cohort study using real world data. British Journal of Cancer. https://doi.org/10.1038/s41416-026-03630-8

Image Credits: AI Generated

DOI: 10.1038/s41416-026-03630-8

Keywords: head and neck cancer, treatment delay, waiting times, NHS England, cancer referral, real-world data, radiotherapy, cancer surgery, health inequalities, cancer epidemiology, diagnostic pathway, British Journal of Cancer